Tag Archive for: Neuraxpharm

Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis

/in

Germany is the first European country to launch ublituximab, with further launches throughout Europe to follow Only B-cell depleting therapy approved for relapsing multiple sclerosis (RMS) that is administered in a 1-hour infusion*, twice per year** Launch follows ex-US commercialisation*** agreement with TG Therapeutics announced August 2023 Barcelona and Düsseldorf – 26 February 2024 – Neuraxpharm Group […]

Read more

Update on Regulatory Review of leriglitazone in the EU

/in

A re-examination for cerebral adrenoleukodystrophy (cALD) will be requested following a negative CHMP opinion Barcelona, Spain and Düsseldorf, Germany – 26 January, 2024 – Minoryx Therapeutics, a late stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused […]

Read more

European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm

/in

Decision is not due to any public health concerns regarding generic DMF products Neuraxpharm to swiftly contest this decision at the General Court of the European Union Barcelona and Düsseldorf – 20 December, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces […]

Read more

Optimum’s Year-End Review  

/in

2023 was an exciting year for Optimum’s clients who overcame many of the market challenges to make significant strides forward with their vital life sciences research. Here are some of the highlights from what has been an exceptionally busy and successful year.   M&A & deals Synaffix continued to build momentum – Lonza acquired the […]

Read more

TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

/in

Total deal size of approximately ~$650M, including over $150M in upfront and near-term milestones Neuraxpharm’s dedicated neurology focus and established European presence makes them an attractive partner for BRIUMVI’s European launch, targeted within the next six months TG retains strategic flexibility with an option to buy back all rights under this agreement if TG is […]

Read more
© Optimum Strategic Communications.